Results 191 to 200 of about 2,675,009 (295)

Correction: Patient-reported outcome measures and physical function following head and neck lymphedema - a systematic review. [PDF]

J Cancer Surviv
Gaitatzis K, Thompson B, Blake FT, Koelmeyer L.   +3 more
europepmc   +1 more source

PAR7 ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG OSTEOARTHRITIC PATIENTS

, 2004
SR Gandra, LW Lawrence
openalex   +1 more source

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance [PDF]

, 2006

openalex   +1 more source

Patient‐reported outcomes (PROs) versus patient‐reported outcome measures (PROMs)—Is there a difference? [PDF]

Clinical and Experimental Dental Research, 2018
openaire   +3 more sources

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Patient-Reported Outcome Measures in Clinical Practice for Tooth Wear: A Literature Review. [PDF]

J Clin Med
Argolinha I, Lobo S, Vieira A, Botelho J, Rua J, Mendes JJ, Machado V.   +6 more
europepmc   +1 more source

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial [PDF]

, 2006
Dafna D. Gladman, Philip J. Mease, M. Cifaldi, Renee Perdok, Eric H. Sasso, J Medich   +5 more
openalex   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Validation of the Seizure-Related Impact Assessment Scale: A Novel Patient-Reported Outcome Measure for Epilepsy. [PDF]

Neurology
Foster E, Conquest A, Ewart C, Nicolo JP, Rayner G, Winton-Brown TT, O'Brien TJ, Kwan P, Malpas C, French J.   +9 more
europepmc   +1 more source

Effect of patient characteristics on reported outcomes after total knee replacement [PDF]

, 2006
Antonio Escobar, José M. Quintana, Amaia Bilbao, Jesús Azkárate, José Ignacio Güenaga, Juan Carlos Arenaza, Luis‐Felipe Gutiérrez   +6 more
openalex   +1 more source